LIPOCINE INC (LPCN) Stock Price, Quote, News and Overview
NASDAQ:LPCN - Nasdaq - US53630X2036 - Common Stock - Currency: USD
LPCN Quote, Performance and Key Statistics
3.38
-0.21 (-5.85%)
The current stock price of LPCN is 3.38 USD. In the past month the price decreased by -25.55%. In the past year, price decreased by -11.29%.
LPCN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About LPCN
Company Profile
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 17 full-time employees. The company went IPO on 2014-03-21. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. The company is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Company Info
LIPOCINE INC
675 S Arapeen Dr Ste 202
Salt Lake City UTAH 84108 US
CEO: Mahesh V. Patel
Employees: 17
Company Website: https://www.lipocine.com/
Investor Relations: https://ir.lipocine.com/
Phone: 18019947383
LIPOCINE INC / LPCN FAQ
What is the stock price of LIPOCINE INC today?
The current stock price of LPCN is 3.38 USD. The price decreased by -5.85% in the last trading session.
What is the ticker symbol for LIPOCINE INC stock?
The exchange symbol of LIPOCINE INC is LPCN and it is listed on the Nasdaq exchange.
On which exchange is LPCN stock listed?
LPCN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LIPOCINE INC stock?
7 analysts have analysed LPCN and the average price target is 10.2 USD. This implies a price increase of 201.78% is expected in the next year compared to the current price of 3.38. Check the LIPOCINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LIPOCINE INC worth?
LIPOCINE INC (LPCN) has a market capitalization of 18.08M USD. This makes LPCN a Nano Cap stock.
How many employees does LIPOCINE INC have?
LIPOCINE INC (LPCN) currently has 17 employees.
What are the support and resistance levels for LIPOCINE INC (LPCN) stock?
LIPOCINE INC (LPCN) has a resistance level at 3.64. Check the full technical report for a detailed analysis of LPCN support and resistance levels.
Is LIPOCINE INC (LPCN) expected to grow?
The Revenue of LIPOCINE INC (LPCN) is expected to grow by 436.5% in the next year. Check the estimates tab for more information on the LPCN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LIPOCINE INC (LPCN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LPCN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LPCN, evaluating the profitability, health, valuation and growth aspects
- LIPOCINE INC (LPCN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LIPOCINE INC (LPCN) Sales and EPS estimates to see what analysts future expectations are.
- LIPOCINE INC (LPCN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LIPOCINE INC (LPCN) Insider and Institutional Ownership to learn about the owners and their transactions.
- LIPOCINE INC (LPCN) Stock Chart to make your own analysis
- LIPOCINE INC (LPCN) Latest news and press-releases to stay up to date.
Does LIPOCINE INC (LPCN) stock pay dividends?
LPCN does not pay a dividend.
When does LIPOCINE INC (LPCN) report earnings?
LIPOCINE INC (LPCN) will report earnings on 2025-03-05, after the market close.
What is the Price/Earnings (PE) ratio of LIPOCINE INC (LPCN)?
LIPOCINE INC (LPCN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.74).
What is the Short Interest ratio of LIPOCINE INC (LPCN) stock?
The outstanding short interest for LIPOCINE INC (LPCN) is 1.5% of its float. Check the ownership tab for more information on the LPCN short interest.
LPCN Technical Analysis
LPCN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LPCN. No worries on liquidiy or solvency for LPCN as it has an excellent financial health rating, but there are worries on the profitability.
LPCN Financial Highlights
Over the last trailing twelve months LPCN reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 76.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.6% | ||
| ROE | -21.22% | ||
| Debt/Equity | 0 |
LPCN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to LPCN. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 75.59% and a revenue growth 436.5% for LPCN